Join our daily newsletter At The Bell to receive exclusive market insights
- Resonance Health (RHT) signs an agreement with Thalassaemia International Federation (TIF) to deploy 500 FerriSmart vouchers to low and middle income nations
- Under the letter of agreement, TIF will engage with National Thalassaemia Associations and physicians to facilitate the use of FerriSmart in clinical management protocols
- To support TIF, Resonance will provide salary support of EU10,000 (A$15,709) for a dedicated and experienced TIF executive
- Data collected from the FerriSmart Access Initiative will be used in TIF’s Global Thalassaemia Review, as well as by Resonance Health to improve and refine its product offerings
- Resonance Health was up 5 per cent, trading at 10.5 cents at 2:40 pm AEDT
Resonance Health (RHT) has signed an agreement with Thalassaemia International Federation.
Through the agreement, Thalassaemia International Federation (TIF) will deploy 500 FerriSmart vouchers to low and middle income countries in Asia, the West Pacific and Europe.
FerriSmart is an AI-driven system for automated real-time measurement of liver-iron concentrate (LIC) in patients, using non-invasive MRI-based technology.
These vouchers will be provided by Resonance Health at no cost.
Under the letter of agreement, TIF will engage with National Thalassaemia Associations and physicians to facilitate the use of FerriSmart to integrate the iron-load monitoring into clinical management protocols.
“FerriSmart is a breakthrough for Thalassaemia patients in low-and-middle income countries where thalassaemia is unfortunately and sadly often sub-optimally managed and the inability to accurately assess LIC contributes to this,” TIF Executive Director Dr. Androulla Eleftheriou said.
Data collected from the FerriSmart Access Initiative will be used in TIF’s Global Thalassaemia Review, as well as by Resonance Health to improve and refine its product offerings.
“Our immediate objective is to ensure that patients and clinicians across the world learn of FerriSmart and have an opportunity to use it and benefit from it,” said Mitchell Wells, Managing Director of Resonance Health.
To support TIF, Resonance will also provide salary support of EU10,000 (A$15,709), paid in instalments over 12 months, for a dedicated and experienced TIF executive.
TIF will also introduce Resonance Health to local leaders, which the company said is a critical part of establishing long-term sustainable commercial product success in new markets.
Resonance Health was up 5 per cent, trading at 10.5 cents at 2:40 pm AEDT.
